Ascendis Pharma A/S (ASND) Projected to Post Quarterly Earnings on Wednesday

Ascendis Pharma A/S (NASDAQ:ASND) will likely be announcing its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.31) per share and revenue of $117.11 million for the quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $130.66 on Monday. The stock has a market capitalization of $7.93 billion, a P/E ratio of -16.17 and a beta of 0.65. The business’s fifty day moving average is $133.63 and its two-hundred day moving average is $132.85. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00.

Analyst Ratings Changes

Several brokerages have recently commented on ASND. TD Cowen reduced their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective for the company. Oppenheimer dropped their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $191.57.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.